Bionomics Limited (BNOX)

Market Cap	8.73M
Revenue (ttm)	176,936
Net Income (ttm)	-16.72M
Shares Out	8.16M
EPS (ttm)	-140.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,801
Open	1.05
Previous Close	1.00
Day's Range	1.05 - 1.10
52-Week Range	0.93 - 10.90
Beta	1.75
Analysts	Strong Buy
Price Target	10.00 (+834.58%)
Earnings Date	n/a

About BNOX

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2021
• Country: Australia
• Stock Exchange: NASDAQ
• Ticker Symbol: BNOX

Financial Performance

Financial numbers in AUD

Analyst Forecast

According to 4 analysts, the average rating for BNOX stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 834.58% from the latest price.

Price Target

$10.0

(834.58% upside)

Analyst Consensus: Strong Buy